Lead Product(s) : JQ-1,Molibresib,Venetoclax
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
UNH Researchers Discover New Inhibitor Drug Combination for Rare Form of Cancer
Details : Researchers at the University found that adding venetoclax or panabinostat to the inhibitors was more effective than adding ibrutinib—with panobinostat offering the greatest combination therapy.
Product Name : JQ-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2021
Lead Product(s) : JQ-1,Molibresib,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Molibresib,Vinorelbine Tartrate
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Targeted Drug Combo Attacks Breast Cancer Brain Metastases in Mice
Details : The two drugs are tubulin inhibitor, vinorelbine, approved by the U.S. Food and Drug Administration (FDA) and available in clinics, and bromodomain inhibitor, I-BET-762, FDA approved for clinical trials.
Product Name : I-BET-762
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2020
Lead Product(s) : Molibresib,Vinorelbine Tartrate
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable